Replies to post #23516 on The Rising Influence of Rising Affluence

[biocqr]

I don’t necessarily agree that our discussion of PVCX is moot

It's moot in the sense that the revelation of an additional competitor with a similar or even superior platform who's well funded, far more clinically advanced and with a major biopharma partner blows up the investment thesis in PCVX.

I wonder if Vaxcyte mgt felt pressure to IPO fearing with every advance by Affinivax they would look less attractive to investors.